Cardiovascular adverse effects of anti-inflammatory drugs

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 12, Issue 1, 2013, Pages 55-67

  Roubille, Camille ^a   Martel Pelletier, Johanne ^a   Davy, Jean Marc ^b   Haraoui, Boulos ^a   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Anti inflammatory agents; Cardiovascular diseases; Cardiovascular system; Cyclooxygenase; Glucocorticoids; Inhibitors; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; GLUCOCORTICOID; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PLACEBO; PREDNISOLONE; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

BLOOD PRESSURE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COLORECTAL ADENOMA; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY REPERFUSION; DEATH; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY TUBULE DISORDER; LOW DRUG DOSE; META ANALYSIS (TOPIC); NONHUMAN; OBESITY; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SODIUM RETENTION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; GLUCOCORTICOIDS; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84875823010     PISSN: 18715230     EISSN: 1875614X     Source Type: Journal    
DOI: 10.2174/1871523011312010008     Document Type: Review

References (75)

1. FitzGerald, G.A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345(6), 433-442.
2. Trelle, S.; Reichenbach, S.; Wandel, S.; Hildebrand, P.; Tschannen, B.; Villiger, P. M.; Egger, M.; Juni, P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. Bmj, 2011, 342, c7086.
3. Antman, E.M.; Bennett, J.S.; Daugherty, A.; Furberg, C.; Roberts, H.; Taubert, K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: A scientific statement from the American Heart Association. Circulation, 2007, 115(12), 1634-1642.
4. Hochberg, M.C.; Altman, R.D.; April, K.T.; Benkhalti, M.; Guyatt, G.; McGowan, J.; Towheed, T.; Welch, V.; Wells, G.; Tugwell, P.; American College of, R. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res., 2012, 64(4), 465-674.
5. Rostom, A.; Muir, K.; Dube, C.; Jolicoeur, E.; Boucher, M.; Joyce, J.; Tugwell, P.; Wells, G.W. Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane Collaboration systematic review. Clin. Gastroenterol. Hepatol., 2007, 5(7), 818-828, 828 e1-5; quiz 768.
6. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, T.K.; Schnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343(21), 1520-8, 2 p following 1528.
7. Weir, M.R.; Sperling, R.S.; Reicin, A.; Gertz, B.J. Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program. Am. Heart. J., 2003, 146(4), 591-604.
8. Konstam, M.A.; Weir, M.R.; Reicin, A.; Shapiro, D.; Sperling, R.S.; Barr, E.; Gertz, B.J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation, 2001, 104(19), 2280-2288.
9. Solomon, D.H.; Schneeweiss, S.; Glynn, R.J.; Kiyota, Y.; Levin, R.; Mogun, H.; Avorn, J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 2004, 109(17), 2068-2073.
10. Kimmel, S.E.; Berlin, J.A.; Reilly, M.; Jaskowiak, J.; Kishel, L.; Chittams, J.; Strom, B.L. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med., 2005, 142(3), 157-164.
11. Levesque, L.E.; Brophy, J.M.; Zhang, B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann. Intern. Med., 2005, 142 (7), 481-489.
12. Graham, D.J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W.A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet, 2005, 365(9458), 475-481.
13. Juni, P.; Nartey, L.; Reichenbach, S.; Sterchi, R.; Dieppe, P.A.; Egger, M. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet, 2004, 364(9450), 2021-2029.
14. Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Quan, H.; Riddell, R.; Lanas, A.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Loftus, S.; Morton, D.G. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 2006, 131(6), 1674-1682.
15. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352(11), 1092-1102.
16. Baron, J.A.; Sandler, R.S.; Bresalier, R.S.; Lanas, A.; Morton, D. G.; Riddell, R.; Iverson, E.R.; Demets, D.L. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet, 2008, 372(9651), 1756-1764.
17. Garner, S.E.; Fidan, D.D.; Frankish, R.R.; Judd, M.G.; Towheed, T.E.; Wells, G.; Tugwell, P. Rofecoxib for rheumatoid arthritis. Cochrane. Database Syst. Rev., 2005, (1), CD003685.
18. Kerr, D.J.; Dunn, J. A.; Langman, M.J.; Smith, J.L.; Midgley, R. S.; Stanley, A.; Stokes, J.C.; Julier, P.; Iveson, C.; Duvvuri, R.; McConkey, C.C. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N. Engl. J. Med., 2007, 357(4), 360-369.
19. Zhang, J.; Ding, E.L.; Song, Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA, 2006, 296(13), 1619-1632.
20. Bertagnolli, M.M.; Eagle, C.J.; Zauber, A.G.; Redston, M.; Solomon, S.D.; Kim, K.; Tang, J.; Rosenstein, R.B.; Wittes, J.; Corle, D.; Hess, T.M.; Woloj, G.M.; Boisserie, F.; Anderson, W.F.; Viner, J.L.; Bagheri, D.; Burn, J.; Chung, D C.; Dewar, T.; Foley, T.R.; Hoffman, N.; Macrae, F.; Pruitt, R.E.; Saltzman, J.R.; Salzberg, B.; Sylwestrowicz, T.; Gordon, G. B.; Hawk, E. T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med., 2006, 355 (9), 873-884.
21. Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352(11), 1071-1080.
22. Antman, E.M.; DeMets, D.; Loscalzo, J. Cyclooxygenase inhibition and cardiovascular risk. Circulation, 2005, 112(5), 759-770.
23. Solomon, S.D.; Pfeffer, M. A.; McMurray, J.J.; Fowler, R.; Finn, P.; Levin, B.; Eagle, C.; Hawk, E.; Lechuga, M.; Zauber, A.G.; Bertagnolli, M.M.; Arber, N.; Wittes, J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 2006, 114(10), 1028-1035.
24. Gislason, G.H.; Jacobsen, S.; Rasmussen, J.N.; Rasmussen, S.; Buch, P.; Friberg, J.; Schramm, T.K.; Abildstrom, S.Z.; Kober, L.; Madsen, M.; Torp-Pedersen, C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation, 2006, 113 (25), 2906-2913.
25. Solomon, S.D.; Wittes, J.; Finn, P.V.; Fowler, R.; Viner, J.; Bertagnolli, M.M.; Arber, N.; Levin, B.; Meinert, C.L.; Martin, B.; Pater, J.L.; Goss, P.E.; Lance, P.; Obara, S.; Chew, E.Y.; Kim, J.; Arndt, G.; Hawk, E. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis. Circulation, 2008, 117(16), 2104-2113.
26. Silverstein, F. E.; Faich, G.; Goldstein, J.L.; Simon, L.S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W.F.; Burr, A.M.; Zhao, W. W.; Kent, J.D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000, 284(10), 1247-1255.
27. Farkouh, M.E.; Kirshner, H.; Harrington, R.A.; Ruland, S.; Verheugt, F.W.; Schnitzer, T.J.; Burmester, G.R.; Mysler, E.; Hochberg, M.C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Gimona, A.; Matchaba, P.; Hawkey, C. J.; Chesebro, J.H. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet, 2004, 364 (9435), 675-684.
28. Ott, E.; Nussmeier, N.A.; Duke, P.C.; Feneck, R.O.; Alston, R.P.; Snabes, M.C.; Hubbard, R.C.; Hsu, P.H.; Saidman, L.J.; Mangano, D.T. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., 2003, 125(6), 1481-1492.
29. Nussmeier, N.A.; Whelton, A.A.; Brown, M.T.; Langford, R.M.; Hoeft, A.; Parlow, J.L.; Boyce, S.W.; Verburg, K.M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med., 2005, 352(11), 1081-1091.
30. Cannon, C.P.; Curtis, S.P.; FitzGerald, G.A.; Krum, H.; Kaur, A.; Bolognese, J. A.; Reicin, A. S.; Bombardier, C.; Weinblatt, M. E.; van der Heijde, D.; Erdmann, E.; Laine, L. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet, 2006, 368(9549), 1771-1781.
31. Combe, B.; Swergold, G.; McLay, J.; McCarthy, T.; Zerbini, C.; Emery, P.; Connors, L.; Kaur, A.; Curtis, S.; Laine, L.; Cannon, C. P. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford), 2009, 48(4), 425-432.
32. Baraf, H. S.; Fuentealba, C.; Greenwald, M.; Brzezicki, J.; O'Brien, K.; Soffer, B.; Polis, A.; Bird, S.; Kaur, A.; Curtis, S.P. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J. Rheumatol., 2007, 34(2), 408-420.
33. Krueger, K.; Lino, L.; Dore, R.; Radominski, S.; Zhang, Y.; Kaur, A.; Simpson, R.; Curtis, S. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann. Rheum. Dis., 2008, 67(3), 315-322.
34. Trelle, S.; Reichenbach, S.; Wandel, S.; Hildebrand, P.; Tschannen, B.; Villiger, P.M.; Egger, M.; Juni, P. Cardiovascular safety of nonsteroidal anti-inflammatory drugs: network meta-analysis. BMJ, 342, c7086.
35. Reginster, J.Y.; Malmstrom, K.; Mehta, A.; Bergman, G.; Ko, A. T.; Curtis, S.P.; Reicin, A.S. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann. Rheum. Dis., 2007, 66(7), 945-951.
36. Curtis, S.P.; Ko, A.T.; Bolognese, J.A.; Cavanaugh, P.F.; Reicin, A. S. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr. Med. Res. Opin., 2006, 22(12), 2365-2374.
37. Rossat, J.; Maillard, M.; Nussberger, J.; Brunner, H.R.; Burnier, M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther., 1999, 66(1), 76-84.
38. Aw, T.J.; Haas, S.J.; Liew, D.; Krum, H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Intern. Med., 2005, 165(5), 490-496.
39. Krum, H.; Swergold, G.; Gammaitoni, A.; Peloso, P.M.; Smugar, S. S.; Curtis, S. P.; Brater, D.C.; Wang, H.; Kaur, A.; Laine, L.; Weir, M.R.; Cannon, C.P. Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. Cardiovasc. Ther., 2012, 30 (6), 342-350.
40. Schjerning Olsen, A.M.; Fosbol, E.L.; Lindhardsen, J.; Folke, F.; Charlot, M.; Selmer, C.; Lamberts, M.; Bjerring Olesen, J.; Kober, L.; Hansen, P.R.; Torp-Pedersen, C.; Gislason, G.H. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation, 2011, 123(20), 2226-2235.
41. Schjerning Olsen, A.M.; Fosbol, E.L.; Lindhardsen, J.; Folke, F.; Charlot, M.; Selmer, C.; Lamberts, M.; Bjerring Olesen, J.; Kober, L.; Hansen, P.R.; Torp-Pedersen, C.; Gislason, G.H. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation, 2011, 123(20), 2226-2235.
42. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin. Trials, 2006, 1(7), e33.
43. Brochier, M.L. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur. Heart. J., 1993, 14(7), 951-957.
44. Kearney, P.M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 2006, 332(7553), 1302-1308.
45. Panoulas, V.F.; Douglas, K.M.; Stavropoulos-Kalinoglou, A.; Metsios, G.S.; Nightingale, P.; Kita, M. D.; Elisaf, M. S.; Kitas, G.D. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford), 2008, 47(1), 72-75.
46. Da Silva, J.A.; Jacobs, J.W.; Kirwan, J.R.; Boers, M.; Saag, K.G.; Ines, L.B.; de Koning, E.J.; Buttgereit, F.; Cutolo, M.; Capell, H.; Rau, R.; Bijlsma, J.W. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann. Rheum. Dis., 2006, 65(3), 285-293.
47. Walker, B.R. Glucocorticoids and cardiovascular disease. Eur. J. Endocrinol., 2007, 157 (5), 545-559.
48. Wei, L.; MacDonald, T.M.; Walker, B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med., 2004, 141(10), 764-770.
49. Hoes, J.N.; Jacobs, J.W.; Boers, M.; Boumpas, D.; Buttgereit, F.; Caeyers, N.; Choy, E.H.; Cutolo, M.; Da Silva, J.A.; Esselens, G.; Guillevin, L.; Hafstrom, I.; Kirwan, J.R.; Rovensky, J.; Russell, A.; Saag, K.G.; Svensson, B.; Westhovens, R.; Zeidler, H.; Bijlsma, J.W. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann. Rheum. Dis., 2007, 66(12), 1560-1567.
50. Souverein, P.C.; Berard, A.; Van Staa, T.P.; Cooper, C.; Egberts, A.C.; Leufkens, H.G.; Walker, B.R. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart, 2004, 90(8), 859-865.
51. Ruyssen-Witrand, A.; Fautrel, B.; Saraux, A.; Le Loet, X.; Pham, T. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine, 2011, 78(1), 23-30.
52. del Rincon, I.; O'Leary, D.H.; Haas, R.W.; Escalante, A. Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum., 2004, 50(12), 3813-3822.
53. Wolfe, F.; Michaud, K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum., 2008, 58(9), 2612-2621.
54. Sihvonen, S.; Korpela, M.; Mustonen, J.; Huhtala, H.; Karstila, K.; Pasternack, A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J. Rheumatol., 2006, 33(9), 1740-1746.
55. Doria, A.; Shoenfeld, Y.; Wu, R.; Gambari, P.F.; Puato, M.; Ghirardello, A.; Gilburd, B.; Corbanese, S.; Patnaik, M.; Zampieri, S.; Peter, J.B.; Favaretto, E.; Iaccarino, L.; Sherer, Y.; Todesco, S.; Pauletto, P. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis., 2003, 62(11), 1071-1077.
56. Svenungsson, E.; Jensen-Urstad, K.; Heimburger, M.; Silveira, A.; Hamsten, A.; de Faire, U.; Witztum, J. L.; Frostegard, J. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation, 2001, 104(16), 1887-1893.
57. de Vries, W.B.; Karemaker, R.; Mooy, N.F.; Strengers, J.L.; Kemperman, H.; Baerts, W.; Veen, S.; Visser, G.H.; Heijnen, C.J.; van Bel, F. Cardiovascular follow-up at school age after perinatal glucocorticoid exposure in prematurely born children: perinatal glucocorticoid therapy and cardiovascular follow-up. Arch. Pediatr. Adolesc. Med., 2008, 162(8), 738-744.
58. Dalziel, S.R.; Walker, N.K.; Parag, V.; Mantell, C.; Rea, H.H.; Rodgers, A.; Harding, J.E. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet, 2005, 365(9474), 1856-1862.
59. Avina-Zubieta, J.A.; Abrahamowicz, M.; Choi, H.K.; Rahman, M. M.; Sylvestre, M.P.; Esdaile, J.M.; Lacaille, D. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study. Ann. Rheum. Dis., 2011, 70(6), 990-995.
60. Bernatsky, S.; Hudson, M.; Suissa, S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology, 2005, 44(5), 677-680.
61. Maradit Kremers, H.; Reinalda, M. S.; Crowson, C.S.; Davis, J.M. 3rd; Hunder, G.G.; Gabriel, S.E. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum., 2007, 57(2), 279-286.
62. Asanuma, Y.; Oeser, A.; Shintani, A.K.; Turner, E.; Olsen, N.; Fazio, S.; Linton, M.F.; Raggi, P.; Stein, C. M. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med., 2003, 349(25), 2407-2415.
63. Roman, M.J.; Shanker, B.A.; Davis, A.; Lockshin, M.D.; Sammaritano, L.; Simantov, R.; Crow, M.K.; Schwartz, J.E.; Paget, S.A.; Devereux, R.B.; Salmon, J.E. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med., 2003, 349(25), 2399-2406.
64. Solomon, D.H.; Karlson, E.W.; Rimm, E.B.; Cannuscio, C.C.; Mandl, L.A.; Manson, J.E.; Stampfer, M.J.; Curhan, G.C. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation, 2003, 107(9), 1303-1307.
65. Yanovski, J.A.; Cutler, G.B. Jr. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinology and metabolism Clin. N. Am., 1994, 23(3), 487-509.
66. Davis, J.M. 3rd; Maradit-Kremers, H.; Gabriel, S.E. Use of lowdose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J. Rheumatol., 2005, 32 (10), 1856-1862.
67. Davis, J.M. 3rd; Maradit Kremers, H.; Crowson, C.S.; Nicola, P.J.; Ballman, K.V.; Therneau, T.M.; Roger, V.L.; Gabriel, S.E. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum., 2007, 56(3), 820-830.
68. Kirwan, J.R. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N. Engl. J. Med., 1995, 333(3), 142-146.
69. van Everdingen, A.A.; Jacobs, J. W.; Siewertsz Van Reesema, D.R.; Bijlsma, J.W. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebocontrolled clinical trial. Ann. Intern. Med., 2002, 136(1), 1-12.
70. Capell, H.A.; Madhok, R.; Hunter, J.A.; Porter, D.; Morrison, E.; Larkin, J.; Thomson, E.A.; Hampson, R.; Poon, F.W. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: Results of a randomised controlled trial. Ann. Rheum. Dis., 2004, 63(7), 797-803.
71. Wassenberg, S.; Rau, R.; Steinfeld, P.; Zeidler, H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double-blind, placebocontrolled trial. Arthritis Rheum., 2005, 52(11), 3371-3380.
72. Landewe, R.B.; Boers, M.; Verhoeven, A.C.; Westhovens, R.; van de Laar, M.A.; Markusse, H.M.; van Denderen, J.C.; Westedt, M.L.; Peeters, A.J.; Dijkmans, B.A.; Jacobs, P.; Boonen, A.; van der Heijde, D. M.; van der Linden, S. COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis Rheum., 2002, 46(2), 347-356.
73. Hafstrom, I.; Rohani, M.; Deneberg, S.; Wornert, M.; Jogestrand, T.; Frostegard, J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. J. Rheumatol., 2007, 34(9), 1810-1816.
74. Hadoke, P.W.; Iqbal, J.; Walker, B.R. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br. J. Pharmacol., 2009, 156(5), 689-712.
75. Kelly, J.J.; Mangos, G.; Williamson, P.M.; Whitworth, J.A. Cortisol and hypertension. Clin. Exp. Pharmacol. Physiol. Suppl., 1998, 25, S51-556.